445 related articles for article (PubMed ID: 35414042)
21. Understanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond.
Shin E; Bak SH; Park T; Kim JW; Yoon SR; Jung H; Noh JY
Front Immunol; 2023; 14():1192907. PubMed ID: 37539051
[TBL] [Abstract][Full Text] [Related]
22. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
[TBL] [Abstract][Full Text] [Related]
23. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
Ruppel KE; Fricke S; Köhl U; Schmiedel D
Front Immunol; 2022; 13():822298. PubMed ID: 35371071
[TBL] [Abstract][Full Text] [Related]
24. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
25. Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy.
Chaudhry K; Dowlati E; Bollard CM
Expert Rev Clin Immunol; 2021 Jun; 17(6):643-659. PubMed ID: 33821731
[No Abstract] [Full Text] [Related]
26. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
27. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
Gaggero S; Witt K; Carlsten M; Mitra S
Front Immunol; 2020; 11():621225. PubMed ID: 33584718
[TBL] [Abstract][Full Text] [Related]
28. Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer.
Iyoda T; Yamasaki S; Ueda S; Shimizu K; Fujii SI
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830717
[TBL] [Abstract][Full Text] [Related]
29. Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.
Islam R; Pupovac A; Evtimov V; Boyd N; Shu R; Boyd R; Trounson A
Cells; 2021 Apr; 10(5):. PubMed ID: 33946954
[TBL] [Abstract][Full Text] [Related]
30. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors.
Lian G; Mak TS; Yu X; Lan HY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008589
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Mehta RS; Rezvani K
Front Immunol; 2018; 9():283. PubMed ID: 29497427
[TBL] [Abstract][Full Text] [Related]
32. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
Front Immunol; 2021; 12():732135. PubMed ID: 34925314
[TBL] [Abstract][Full Text] [Related]
33. Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy.
Chaudhry K; Dowlati E; Long MD; Geiger A; Lang H; Gomez EC; Muniraj N; Sanchez CE; Singh PK; Liu S; Bollard CM; Cruz CRY
Cytotherapy; 2022 Aug; 24(8):802-817. PubMed ID: 35589475
[TBL] [Abstract][Full Text] [Related]
34. Improving efficacy of cancer immunotherapy by genetic modification of natural killer cells.
Burga RA; Nguyen T; Zulovich J; Madonna S; Ylisastigui L; Fernandes R; Yvon E
Cytotherapy; 2016 Nov; 18(11):1410-1421. PubMed ID: 27421740
[TBL] [Abstract][Full Text] [Related]
35. The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers.
Kimpo MS; Oh B; Lee S
Curr Oncol Rep; 2019 Sep; 21(10):93. PubMed ID: 31502008
[TBL] [Abstract][Full Text] [Related]
36. Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy.
Fantini M; Arlen PM; Tsang KY
Front Immunol; 2023; 14():1275904. PubMed ID: 38077389
[TBL] [Abstract][Full Text] [Related]
37. Next Generation Natural Killer Cells for Cancer Immunotherapy.
Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
Front Immunol; 2022; 13():886429. PubMed ID: 35720306
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future.
Stem Cell Res Ther; ; . PubMed ID: 33766099
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]